The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Cytokinetics Inc shares valued at $63,760 were sold by Malik Fady Ibraham on Jun 03 ’25. At $31.88 per share, Malik Fady Ibraham sold 2,000 shares. The insider’s holdings dropped to 140,610 shares worth approximately $4.56 million following the completion of this transaction.
Also, Blum Robert I sold 5,000 shares, netting a total of over 156,100 in proceeds. Following the sale of shares at $31.22 each, the insider now holds 408,108 shares.
Before that, Malik Fady Ibraham had sold 2,000 shares from its account. In a trade valued at $63,960, the EVP Research & Development traded Cytokinetics Inc shares for $31.98 each. Upon closing the transaction, the insider’s holdings decreased to 2,000 shares, worth approximately $4.55 million.
As published in their initiating research note from Barclays on April 24, 2025, Cytokinetics Inc [CYTK] has been an Overweight and the price target has been revised to $55. Analysts at Citigroup started covering the stock with ‘”a Buy”‘ outlook in a report released in early February. As of January 22, 2025, Stifel has initiated its “Buy” rating for CYTK. Earlier on November 08, 2024, RBC Capital Mkts initiated its rating. Their recommendation was “an Outperform” for CYTK stock.
Analyzing CYTK Stock Performance
During the last five days, there has been a surge of approximately 7.03%. Over the course of the year, Cytokinetics Inc shares have dropped approximately -31.10%. Shares of the company reached a 52-week high of $52.80 on 01/27/25 and a 52-week low of $29.31 on 05/15/25.
Support And Resistance Levels for Cytokinetics Inc (CYTK)
According to the 24-hour chart, there is a support level at 32.04, which, if violated, would cause prices to drop to 31.66. In the upper region, resistance lies at 32.77. The next price resistance is at 33.12. RSI (Relative Strength Index) is 46.28 on the 14-day chart, showing neutral technical sentiment.
